Prospective Registry to Evaluate the Effect of the DCISionRT® Test on Treatment Decisions in Patients with Ductal Carcinoma In Situ (DCIS) Following Breast Conserving Therapy.
|Eligibility criteria|| |
To be considered for this registry you must meet the following criteria:
|Study details|| |
Your participation in this registry means information will be collected about your diagnosis, test result (which will be shared with your doctor and radiation oncologist), treatment and outcomes over a 5-year period. In addition, your de-identified results could be used for future medical research by PreludeDx and GenesisCare. Such research may involve the investigation of new methods of diagnosis and treatment, the development of new products, treatment pathways and patient management processes.
|More information|| |
For more information about DCISionRT® click here.
Phone: 1300 086 870